Resources

This document states the outcome of Alexion Pharmaceuticals Australasia's application to include asfotase alfa on the Life Saving Drugs Program.

Health professionals can print this fact sheet and give it to patients who are starting treatment under the Life Saving Drugs Program.

Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for HPP.

Treating physicians use this application form to apply for a patient to access LSDP medication for HPP for the first time, or after a break.

These guidelines contain the general, initial and ongoing eligibility requirements to access asfotase alfa (Strensiq®) for perinatal- and infantile-onset hypophosphatasia under the Life Saving Drugs Program.

This document outlines 51 recommendations from the Life Saving Drugs (LSDP) expert panel review.

This fact sheet explains changes to the way we provide access to eculizumab (Soliris®) for patients with paroxysmal nocturnal haemoglobinuria from 1 March 2022.

This fact sheet for prescribers explains changes to the way we provide access to eculizumab (Soliris®) for patients with paroxysmal nocturnal haemoglobinuria from 1 March 2022. It outlines what prescribers need to do to transition their patients to the new arrangements.

Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 11th meeting on 18th February 2022.

Treating physicians use this application form to apply for a patient to access LSDP medication for Gaucher disease for the first time, or after a break.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS I.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS II.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Fabry disease.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS IVA.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS VI.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Pompe disease.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for paroxysmal nocturnal haemoglobinuria.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for hereditary tyrosinaemia (type 1).

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Batten disease.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Gaucher disease.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS I for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS II for the first time, or after a break.